Buspirone in the treatment of tardive dyskinesia.
Buspirone is a novel anxiolytic chemically unrelated to the benzodiazepines. In clinical trials it has been shown to be as effective as diazepam, with fewer side effects. Buspirone is primarily active in dopaminergic pathways. It has the properties of both a dopamine agonist and antagonist. In this paper a model for treatment of tardive dyskinesia with buspirone is developed, based on dopamine autoreceptor blockade. A clinical trial of buspirone in the treatment of movement disorders is warranted.
D014151:Anti-Anxiety Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002065:Buspirone; D002986:Clinical Trials as Topic; D004298:Dopamine / Q000502:physiology; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy*; D006801:Humans; D010300:Parkinson Disease / Q000503:physiopathology; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use*; D012559:Schizophrenia / Q000503:physiopathology
D014151:Anti-Anxiety Agents; D011743:Pyrimidines; D002065:Buspirone; D004298:Dopamine